A groundbreaking DNA study has identified a link between cancer treatment and blood ageing, a condition in which the body’s red and white blood cells lose their ability to function properly. The research, published recently, found that certain cancer medications can cause genetic changes that accelerate this process.
The study, conducted by researchers at a leading medical institution, analyzed DNA samples from patients who had received chemotherapy or targeted therapy for various types of cancer. By comparing the genetic data of these patients with those who had not undergone treatment, the scientists discovered a significant correlation between blood ageing and exposure to certain cancer drugs.
Specifically, the research found that patients treated with medications containing platinum-based compounds – commonly used to treat ovarian and breast cancers – were more likely to experience accelerated blood ageing. The study’s authors believe that this link may be due to the way these medications damage DNA, leading to a loss of telomeres, which are protective caps on the ends of chromosomes.
The implications of this research are significant, as they suggest that older patients who receive cancer treatment may be more susceptible to age-related health issues. The study’s findings also highlight the need for further research into the long-term effects of cancer medications on blood cells and overall health.
As researchers continue to explore this link between cancer treatment and blood ageing, they hope to develop new treatments that minimize the negative impacts of chemotherapy on patients’ health. In the meantime, the study’s results serve as a reminder of the importance of careful consideration and monitoring when treating patients with cancer.
Source: https://www.ft.com/content/7ed09e6c-2914-4a69-adf4-2de31e604faa